Discovery of a Locally and Orally Active CXCL12 Neutraligand (LIT-927) with Anti-inflammatory Effect in a Murine Model of Allergic Airway Hypereosinophilia
摘要:
We previously reported Chalcone-4 (1) that binds the chemokine CXCL12, not its cognate receptors CXCR4 or CXCR7, and neutralizes its biological activity. However, this neutraligand suffers from limitations such as poor chemical stability, solubility, and oral activity. Herein, we report on the discovery of pyrimidinone 57 (LIT-927), a novel neutraligand of CXCL12 which displays a higher solubility than 1 and is no longer a Michael acceptor. While both 1 and 57 reduce eosinophil recruitment in a murine model of allergic airway hypereosinophilia, 57 is the only one to display inhibitory activity following oral administration. Thereby, we here describe 57 as the first orally active CXCL12 neutraligand with anti-inflammatory properties. Combined with a high binding selectivity for CXCL12 over other chemokines, 57 represents a powerful pharmacological tool to investigate CXCL12 physiology in vivo and to explore the activity of chemokine neutralization in inflammatory and related diseases.
We synthesized twelve hybrids based on curcumin and resveratrol, and their structures were elucidated by spectroscopic analysis. The chemopreventive potential of these compounds was evaluated against SW480 human colon adenocarcinoma cells, its metastatic derivative SW620, along with the non-malignant CHO-K1 cell line. Among the tested compounds, hybrids 3e and 3i (for SW480) and 3a, 3e and 3k (for
Vanillin enones as selective inhibitors of the cancer associated carbonic anhydrase isoforms IX and XII. The out of the active site pocket for the design of selective inhibitors?
作者:Leonardo E. Riafrecha、Macarena S. Le Pors、Martín J. Lavecchia、Silvia Bua、Claudiu T. Supuran、Pedro A. Colinas
DOI:10.1080/14756366.2021.1982933
日期:2021.1.1
Abstract New C-glycosides and α,β-unsaturated ketones incorporating the 4-hydroxy-3-methoxyphenyl (vanillin) moiety as inhibitors of carbonic anhydrase (CA, EC 4.2.1.1) isoforms have been investigated. The inhibition profile of these compounds is presented against four human CA (hCA) isozymes, comprising hCAs I and II (cytosolic, ubiquitous enzymes) and hCAs IX and XII (tumour associated isozymes)
摘要 新C已经研究了含有 4-羟基-3-甲氧基苯基(香草醛)部分的β-糖苷和 α,β-不饱和酮作为碳酸酐酶(CA,EC 4.2.1.1)异构体的抑制剂。这些化合物对四种人类 CA (hCA) 同工酶具有抑制作用,包括 hCAs I 和 II(细胞溶质、普遍存在的酶)和 hCAs IX 和 XII(肿瘤相关同工酶)。已经对这些酶的活性位点内的抑制剂进行了对接分析并进行了讨论,表明观察到的选择性可以解释为 CA 活性位点之外的替代口袋,其中一些化合物可能结合。几种衍生物被鉴定为肿瘤相关 hCA IX 和 XII 的选择性抑制剂。
TRPV-1 RECEPTOR ANTAGONIST COMPOUND DERIVED FROM 1,3,4-THIADIAZOLE ALKYLAMIDES AND CHALCONES
申请人:UNIVERSIDAD DE CONCEPCION
公开号:US20160039778A1
公开(公告)日:2016-02-11
This technology encompasses compounds derived from 1,3,4-thiadiazole alkylamides and chalcone, which inhibit the activation of the TRPV-1 receptor using capsaicin and temperature. Also disclosed is the use of these compounds in the treatment of diseases with TRPV-1 overexpression, such as chronic pain.